CALA (Calithera Biosciences) Debt-to-EBITDA : -0.06 (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Calithera Biosciences Debt-to-EBITDA?

Calithera Biosciences CALA Debt-to-EBITDA is -0.06 as of Dec. 2022.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Calithera Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $1.53 Mil. Calithera Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.14 Mil. Calithera Biosciences's annualized EBITDA for the quarter that ended in Dec. 2022 was $-29.12 Mil. Calithera Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 was -0.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Calithera Biosciences's Debt-to-EBITDA or its related term are showing as below:

CALA's Debt-to-EBITDA is not ranked *
in the Diversified Financial Services industry.
Industry Median: 5.845
* Ranked among companies with meaningful Debt-to-EBITDA only.

Calithera Biosciences  (OTCPK:CALA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Calithera Biosciences Debt-to-EBITDA Related Terms

Calithera Biosciences Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Calithera Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calithera Biosciences Debt-to-EBITDA Chart

Calithera Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.09 -0.07 -0.05 -0.04

Calithera Biosciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.05 -0.05 -0.05 -0.06

CALA vs PPCB, QBIO, RGMP: Debt-to-EBITDA Comparison

For the Shell Companies subindustry, Calithera Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calithera Biosciences Debt-to-EBITDA vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Calithera Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's Debt-to-EBITDA falls into.


Calithera Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Calithera Biosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.53 + 0.136) / -41.819
=-0.04

Calithera Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.53 + 0.136) / -29.124
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2022) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -0.06 mean?
Calithera Biosciences (CALA) has a Debt-to-EBITDA of -0.06 as of Dec. 2022. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Calithera Biosciences.
Is Calithera Biosciences' Debt-to-EBITDA too high?
Calithera Biosciences' current Debt-to-EBITDA is -0.06.
How does Calithera Biosciences' Debt-to-EBITDA compare to PPCB and QBIO?
Calithera Biosciences' Debt-to-EBITDA of -0.06 can be compared against companies in the Diversified Financial Services industry. The industry median Debt-to-EBITDA is 5.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Diversified Financial Services company?
The median Debt-to-EBITDA among Diversified Financial Services companies is 5.85, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Calithera Biosciences. For the Diversified Financial Services industry, the median Debt-to-EBITDA is 5.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Calithera Biosciences's current Debt-to-EBITDA is -0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calithera Biosciences stock overvalued right now?
Calithera Biosciences (CALA) has a current Debt-to-EBITDA of -0.06. The current Debt-to-EBITDA is -0.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Calithera Biosciences (CALA), the current Debt-to-EBITDA is -0.06 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Calithera Biosciences Business Description

Address 343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a shell company.